EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of March 9, 2018 (the “Effective Date”) by and between Innovate Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and June S. Almenoff, MD, PhD (the “Executive”).
Amended and Restated EMPLOYMENT AGREEMENTEmployment Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This Amended and Restated Employment Agreement (“Restated Agreement”) is executed on the 11th day of March, 2018 (the “Effective Date”) by and between Innovate Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Jay P. Madan (the “Executive”). The Executive and the Company may be referred to herein as a “Party” or collectively as the “Parties.”
SUBLICENSE AGREEMENTSublicense Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • Maryland
This Sublicense Agreement (“Agreement”) effective as of February 19, 2016 (“Effective Date”) is made by and between Alba Therapeutics Corporation, a Delaware corporation (“Alba”), having an address at 100 International Drive, 23rd Floor, Baltimore, MD 21202, and Innovate Biopharmaceuticals, Inc., a Delaware corporation, having an address at 8601 Six Forks Road, Suite 400, Raleigh, NC 27615 (“Innovate”).
LICENSE AGREEMENT effective February 26, 2016 between ALBA THERAPEUTICS CORPORATION and INNOVATE BIOPHARMACEUTICALS, INC.License Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This License Agreement (“Agreement”) effective as of February 26, 2016 (“Effective Date”) is made by and between Alba Therapeutics Corporation, a Delaware corporation (“Alba”), having an address at 100 International Drive, 23rd Floor, Baltimore, MD 21202, and Innovate Biopharmaceuticals, Inc., a Delaware corporation, having an address at 8601 Six Forks Road, Suite 400, Raleigh, NC 27615 (“Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is entered into October 28, 2015, (the “Effective Date”) by and between Innovate Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Jay P. Madan (the “Executive”), an individual, (collectively, the “Parties”).
APAZA LICENSE AGREEMENT between SEACHAID PHARMACEUTICALS, INC. and GI THERAPEUTICS, INC. Dated as of April 19, 2013 APAZA LICENSE AGREEMENTLicense Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This License Agreement (the “Agreement”) is entered into this 19th day of April, 2013 (the “Effective Date”), by and among Seachaid Pharmaceuticals, Inc., a Delaware corporation (“Licensor”), and GI Therapeutics, Inc., a North Carolina corporation (“Licensee”). Licensee and Licensor may each be referred to in this Agreement individual as a “Party” and collectively as the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of November 2, 2015 (the “Effective Date”) by and between Innovate Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Christopher P. Prior, Ph.D. (the “Executive”), an individual residing in Delaware County, Pennsylvania.
SEPARATION AGREEMENT AND RELEASE OF CLAIMSSeparation Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • California
This Separation Agreement and Release of Claims (the “Agreement”) is entered into by and between David Olert (hereinafter “Employee”) and Monster Digital, Inc., its officers, directors, employees, agents and affiliates (hereinafter “the Company”).
AGREEMENT FOR CONSULTING SERVICESConsulting Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This CONSULTING AGREEMENT (this “Agreement”) is made by and among INNOVATE BIOPHARMACEUTICALS, INC. (“COMPANY”), a Delaware corporation, with its principal place of business at 8480 Honeycutt Road, Suite 120, Raleigh, NC 27615, and DAVID OLERT (“CONSULTANT”) effective as of this 17th day of February, 2018. Capitalized terms used by not defined herein shall have the meanings ascribed to such terms in the Agreement and Plan of Merger and Reorganization by and among Monster Digital, Inc. (now Innovate Biopharmaceuticals, Inc.), a wholly owned subsidiary of Monster Digital, Inc., Monster Merger Sub, Inc., a Delaware corporation, and Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.), a Delaware corporation (the “MERGER AGREEMENT”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 14th, 2018 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”) is made and entered into as of December 23rd, 2014 (“Effective Date”) between Innovate Biopharmaceuticals Inc., a Delaware corporation, with offices at 8601 Six Forks Road, Suite 400, Raleigh, North Carolina 27615, (“Innovate”) and Repligen Corporation, a Delaware corporation with offices at 41 Seyon Street, Building 1, Suite 100, Waltham, MA 02453 (“Repligen”). Repligen and Innovate shall also be referred to herein individually as “Party” and collectively as “Parties”.
